Rezo’s disease-specific maps are designed to pinpoint novel, druggable targets that can be attacked with a range of treatment modalities.
The platform enables the rapid identification and study of disease-causing protein and genetic interactions, which would be difficult to discover using traditional, often siloed, scientific methods. Rezo’s Sequence to Systems to Drugs (SSD) platform integrates data from proteomics, genetics, structural biology, and chemical biology approaches using sophisticated computational methods to create comprehensive maps of molecular disease networks. Chemistry pioneer and inventor of leading drugs targeting KRAS, Kevan Shokat, Ph.D., is also a co-founder as well as a professor at UCSF, and an investigator of the Howard Hughes Medical Institute (HHMI). Rezo’s platform is based on technology from the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) developed by Nevan Krogan, Ph.D., director of QBI and a co-founder and chief executive officer of Rezo.
REZO BOBOK HOSSEIN SERIES
The Series A financing was led by SR One, a16z Bio + Health, and Norwest Venture Partners, and also included SV Angel, Liquid 2 Ventures, and Hawktail. 17, 2022 (GLOBE NEWSWIRE) - Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, launched today with $78 million from a Series A financing. Initial drug discovery focus in oncology. Integration of technologies across proteomics, genetics, structural biology, chemistry, and bioinformatics enables advanced insights into disease biology for accelerated drug discovery –
0 kommentar(er)
